Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Core Insights - Adaptive Biotechnologies and NeoGenomics have announced a multi-year exclusive strategic collaboration to enhance minimal residual disease (MRD) monitoring for patients with specific blood cancers [1][2][3] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [9] - NeoGenomics is a leading cancer diagnostics company specializing in cancer genetics testing and information services, offering a comprehensive oncology-focused testing menu [10] Collaboration Details - The partnership will integrate Adaptive's clonoSEQ MRD testing with NeoGenomics' COMPASS and CHART assessment services, providing personalized treatment strategies for blood cancer patients [2][3] - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting MRD in lymphoid cancers, while COMPASS and CHART offer a multi-modal testing approach [2][6] Clinical Implications - The collaboration allows clinicians to confirm blood cancer diagnoses and track patient-specific DNA sequences, enhancing the ability to monitor disease progression and treatment response [4][5] - Patients will have increased access to clinical trials that utilize clonoSEQ for therapy guidance, improving their treatment options [4] Market Position - The partnership reflects a commitment to providing best-in-class diagnostic testing and strengthens both companies' positions in the hematology testing market [5]